A clinical trial to investigate AZD-9150 (ISIS-STAT3-2.5Rx) in combination with durvalumab (MEDI-4736)-Trial 2
Phase of Trial: Phase II
Latest Information Update: 07 May 2015
At a glance
- Drugs AZD 9150 (Primary) ; Durvalumab
- Indications Cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 07 May 2015 Assumed indication as cancer because the MR does not specify the indication. Also, the MR states that the company is planning to initiate 2 trials evaluating this combination. So, I have created this and another identical CTP 256663.
- 07 May 2015 New trial record
- 05 May 2015 According to an AstraZeneca media release, the company plans to initiate two clinical studies evaluating ISIS-STAT3-2.5Rx in combination with MEDI4736 in 2015.